Kura Oncology, Inc. (KURA): Price and Financial Metrics
KURA Price/Volume Stats
| Current price | $9.88 | 52-week high | $16.14 |
| Prev. close | $9.67 | 52-week low | $7.41 |
| Day low | $9.18 | Volume | 67,548 |
| Day high | $9.94 | Avg. volume | 719,741 |
| 50-day MA | $8.78 | Dividend yield | N/A |
| 200-day MA | $10.63 | Market Cap | 733.81M |
KURA Stock Price Chart Interactive Chart >
Kura Oncology, Inc. (KURA) Company Bio
Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. The company was founded in 2014 and is based in La Jolla, California.
Latest KURA News From Around the Web
Below are the latest news stories about KURA ONCOLOGY INC that investors may wish to consider to help them evaluate KURA as an investment opportunity.
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Call TranscriptKura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the Third Quarter 2023 Kura Oncology Inc. Earnings Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] This call is being […] |
Kura Oncology Inc (KURA) Reports Q3 2023 Financial ResultsCompany's Cash Reserves of $452.6 Million Expected to Fund Operations Until Mid-2026 |
Kura Oncology Reports Third Quarter 2023 Financial Results– Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 – – Preliminary data from 20 patients in KOMET-007 combination trial of ziftomenib anticipated early in first quarter of 2024 – – First patient dosed in FIT-001 dose-escalation study of next-generation FTI, KO-2806 – – Clinical collaboration with Mirati to evaluate KO-2806 and adagrasib in KRASG12C-mutated NSCLC – – $452.6 million in cash, cash equivalents and investments pro |
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC– Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) expected to begin dosing patients in combination with adagrasib by mid-2024 –SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced a clinical collaboration and supply agreeme |
Kura Oncology to Participate in Three Upcoming Investor ConferencesSAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences. A virtual fireside chat at the TD Cowen Fall Oncology Innovation Summit: Insights for SITC and ASH event at 12:00 p.m. ET / 9:00 a.m. P |
KURA Price Returns
| 1-mo | 23.65% |
| 3-mo | -1.79% |
| 6-mo | -25.15% |
| 1-year | -36.54% |
| 3-year | -71.03% |
| 5-year | -22.20% |
| YTD | -20.39% |
| 2022 | -11.36% |
| 2021 | -57.13% |
| 2020 | 137.53% |
| 2019 | -2.07% |
| 2018 | -8.24% |
Loading social stream, please wait...